Skip to main content
Atrás
Watch Compare

ORAMED PHARMACEUTICALS INC.

Calidad de datos: 100%
ORMP
Nasdaq Manufacturing Chemicals
$3.50
▲ $0.02 (0.43%)
Cap. Mercado: 141.36 M
Precio
$3.50
Cap. Mercado
141.36 M
Rango del Día
$3.41 — $3.51
Rango de 52 Semanas
$1.98 — $3.76
Volumen
60,900
Apertura $3.45
Promedio 50D / 200D
$3.40
2.81% above
Promedio 50D / 200D
$2.71
29.20% above

Quick Summary

Puntos Clave

Revenue declined -7.25% annually over 5 years
ROE of 35.80% indicates high profitability
Net margin of 3202.50% shows strong profitability
Negative free cash flow of -9.15 M
P/E of 2.21 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 56.50%

Crecimiento

Revenue Growth (5Y)
-7.25%
Below sector avg (1.82%)
Revenue (1Y)49.25%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
35.80%
Above sector avg (-53.41%)
ROIC-6.89%
Net Margin3202.50%
Op. Margin-754.40%

Seguridad

Debt / Equity
N/A
Current Ratio22.24
Interest Coverage-17.69

Valoración

PE (TTM)
2.21
Above sector avg (-1.48)
P/B Ratio0.70
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E 2.2 -1.5
P/B 0.7 1.6
ROE % 35.8 -53.4
Net Margin % 3202.5 -41.5
Rev Growth 5Y % -7.3 1.8
D/E — 0.3

ETFs Holding This Stock

AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0.00% weight
AVUS logo AVUS Avantis U.S. Equity ETF
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 49.25% Revenue Growth (3Y) 22.17%
Earnings Growth (1Y) N/A Earnings Growth (3Y) 240.48%
Revenue Growth (5Y) -7.25% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2.00 M Net Income (TTM) 64.05 M
ROE 35.80% ROA 33.52%
Gross Margin 0.65% Operating Margin -754.40%
Net Margin 3202.50% Free Cash Flow (TTM) -9.15 M
ROIC -6.89% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 22.24
Interest Coverage -17.69 Asset Turnover 0.01
Working Capital 130.00 M Tangible Book Value 203.28 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 2.21 Forward P/E N/A
P/B Ratio 0.70 P/S Ratio 70.68
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -6.48%
Market Cap 141.36 M Enterprise Value 89.18 M
Per Share
EPS (Diluted TTM) 1.50 Revenue / Share 0.05
FCF / Share -0.23 OCF / Share -0.23
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.45% FCF Conversion -14.29%
SBC-Adj. FCF -13.16 M Growth Momentum 56.50

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.00 M 1.34 M 1.34 M 2.70 M 2.70 M
Net Income 64.05 M -19.10 M 5.53 M -37.76 M -22.99 M
EPS (Diluted) 1.50 -0.48 0.14 0.94 —
Gross Profit 13,000.0 — — — —
Operating Income -15.09 M -12.78 M -15.77 M -40.60 M -24.22 M
EBITDA — — — — —
R&D Expenses 6.38 M 6.32 M 8.97 M 27.64 M 20.99 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 853,000.0 2.59 M 2.04 M — —
Income Tax 11.31 M 3.18 M 100,000.0 100,000.0 —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 230.86 M 155.28 M 220.55 M 161.64 M 128.00 M
Total Liabilities — — — — —
Shareholders' Equity 199.74 M 146.27 M 163.82 M 151.81 M 115.77 M
Total Debt 99.55 M 51.01 M 51.01 M 25,000.0 —
Cash & Equivalents 45.95 M — 9.06 M — 77.25 M
Current Assets 133.27 M 143.22 M 162.58 M 157.11 M 95.34 M
Current Liabilities 19.09 M 5.69 M 53.21 M 5.75 M 6.68 M